21H·

Growth market diabetes and obesity

32
11 Comments

profile image
I am betting on $NOVO B in this market.
In general, I often hear that overweight people are "taking away" medication from diabetes patients. I hope there won't be any conflicts at some point.
4
profile image
@TradingHase Well, that may well have been possible due to the bottlenecks. However, $NOVO B has now withdrawn from $MTSR and not outbid. This means that $PFE has won the bidding battle and will take over Metsera $MTSR for up to USD 10 billion. The terms provide for USD 65.60 per share in cash plus up to USD 20.65 in the form of variable payments.

I think that's a good thing because I wouldn't have thought another 10 billion in debt was a good thing in the current situation.
4
profile image
@BamBamInvest I had also read this and wondered whether a purchase of this amount would be good for the company. Of course $MTSR has a good product, but it doesn't have to be at any price.
1
@BamBamInvest The news regarding Metsera is also positive for the time being. It means that $NOVO B and the share price will not be burdened even more. In addition, such a takeover must first be profitable for $PFE. Especially with such high costs. I remain bullish on Novo in the long term.
2
profile image
@Baisse-Jumper $PFIZER buys a promising product that is only in phase 2 and probably won't be ready for the market for another 2 years. I am glad that $NOVO B was sensible in the end and that $MTSR then accepted the $PFE offer, probably also for regulatory reasons. ✌️
2
profile image
Bottom soon in at novo? 😪
2
profile image
@Hands I assume ✌️
1
profile image
I have also been back at $NOVO B since yesterday. I wanted to wait for the 40 euros. 👍
1
profile image
@Olli68 🫡 Welcome to the club 😁
1
profile image
It's funny that it says rice and minced meat instead of just "healthy eating", for example
profile image
@Iwamoto well because they probably don't eat a healthy diet 😄 but I see you've given it some thought.
1
Join the conversation